{
    "id": 454,
    "fullName": "BRAF V600D",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "BRAF V600D (previously reported as V599) lies within the activation segment of the kinase domain of the Braf protein (PMID: 15035987). V600D confers a gain of function to the Braf protein as demonstrated by increased kinase activity, downstream signaling, and the ability to transform cells in vitro (PMID: 15035987).",
            "references": [
                {
                    "id": 146,
                    "pubMedId": 15035987,
                    "title": "Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/15035987"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 673,
        "geneSymbol": "BRAF",
        "terms": [
            "BRAF",
            "B-raf",
            "B-RAF1",
            "BRAF1",
            "NS7",
            "RAFB1"
        ]
    },
    "variant": "V600D",
    "createDate": "05/02/2014",
    "updateDate": "08/17/2017",
    "referenceTranscriptCoordinates": {
        "id": 109416,
        "transcript": "NM_004333",
        "gDna": "chr7:g.140753335_140753336delCAinsGT",
        "cDna": "c.1799_1800delTGinsAC",
        "protein": "p.V600D",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7947,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX7904 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 4606,
                "therapyName": "PLX7904",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3309,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT241161 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3106,
                "therapyName": "CCT241161",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3730,
                    "pubMedId": 17210691,
                    "title": "Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17210691"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7953,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7937,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAK-632 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3300,
                "therapyName": "TAK-632",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11711,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, single Tafinlar (dabrafenib) and subsequent Tafinlar (dabrafenib) and Mekinist (trametinib) combination treatment resulted in disease stablization in a patient with pilocytic astrocytoma harboring BRAF V600D (PMID: 28784858).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 4851,
                "name": "pilocytic astrocytoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9723,
                    "pubMedId": 28784858,
                    "title": "Targeted MAPK Pathway Inhibitors in Patients With Disseminated Pilocytic Astrocytomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28784858"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7907,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZ628 inhibited proliferation of melanoma cell lines harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 1093,
                "therapyName": "AZ628",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3308,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCT196969 inhibited MEK and ERK phosphorylation and growth of melanoma cells harboring BRAF V600D in culture (PMID: 25500121, PMID: 17210691).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3105,
                "therapyName": "CCT196969",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3714,
                    "pubMedId": 25500121,
                    "title": "Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25500121"
                },
                {
                    "id": 3730,
                    "pubMedId": 17210691,
                    "title": "Tumor necrosis factor-alpha blocks apoptosis in melanoma cells when BRAF signaling is inhibited.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17210691"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7961,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tafinlar (dabrafenib) inhibited proliferation of melanoma cells harboring BRAF V600D in culture (PMID: 27523909).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6522,
                    "pubMedId": 27523909,
                    "title": "An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27523909"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20140,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Zelboraf (vemurafenib) treatment resulted in a objective response rate of 44.8% (43/96), median duration of response of 6.4 months, median progression-free survival (PFS) of 5.2 months, and median overall survival of 10 months in non-small cell lung cancer patients with BRAF V600 mutations, with a PFS of 3.8 months in the patient harboring BRAF V600D (PMID: 31959346; NCT02304809).",
            "molecularProfile": {
                "id": 653,
                "profileName": "BRAF V600D"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17717,
                    "pubMedId": 31959346,
                    "title": "Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31959346"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6320,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XL147 inhibited tumor growth in xenograft models of a PTEN-deficient human melanoma cell line harboring BRAF V600D (PMID: 25637314).",
            "molecularProfile": {
                "id": 23100,
                "profileName": "BRAF V600D PTEN loss"
            },
            "therapy": {
                "id": 1050,
                "therapyName": "XL147",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5522,
                    "pubMedId": 25637314,
                    "title": "The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25637314"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a melanoma cell line harboring BRAF V600D and knockdown of NRAS demonstrated a decreased response to Mektovi (binimetinib) relative to cells without NRAS knockdown in culture (PMID: 29245078).",
            "molecularProfile": {
                "id": 31592,
                "profileName": "BRAF V600D NRAS dec exp"
            },
            "therapy": {
                "id": 807,
                "therapyName": "Binimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14368,
                    "pubMedId": 29245078,
                    "title": "Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29245078"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 653,
            "profileName": "BRAF V600D",
            "profileTreatmentApproaches": [
                {
                    "id": 14680,
                    "name": "BRAF Inhibitor",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14683,
                    "name": "MEK2 Inhibitor",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14682,
                    "name": "MEK1 Inhibitor",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14684,
                    "name": "RAF Inhibitor (Pan)",
                    "profileName": "BRAF V600D"
                },
                {
                    "id": 14681,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "BRAF V600D"
                }
            ]
        },
        {
            "id": 23100,
            "profileName": "BRAF V600D PTEN loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31592,
            "profileName": "BRAF V600D NRAS dec exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 109416,
            "transcript": "NM_004333",
            "gDna": "chr7:g.140753335_140753336delCAinsGT",
            "cDna": "c.1799_1800delTGinsAC",
            "protein": "p.V600D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 109415,
            "transcript": "XM_005250045",
            "gDna": "chr7:g.140753335_140753336delCAinsGT",
            "cDna": "c.1799_1800delTGinsAC",
            "protein": "p.V600D",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}